-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Xeruborbactam in Acinetobacter Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Xeruborbactam in Acinetobacter Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Xeruborbactam in Acinetobacter Infections Drug Details: Xeruborbactam is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Xeruborbactam in Enterobacteriaceae Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Xeruborbactam in Enterobacteriaceae Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Xeruborbactam in Enterobacteriaceae Infections Drug Details: Xeruborbactam is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Xeruborbactam in Pseudomonas aeruginosa Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Xeruborbactam in Pseudomonas aeruginosa Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Xeruborbactam in Pseudomonas aeruginosa Infections Drug Details: Xeruborbactam is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ORAvance in Gram-Negative Bacterial Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ORAvance in Gram-Negative Bacterial Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ORAvance in Gram-Negative Bacterial Infections Drug Details: ORAvance is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Ceftibuten + Xeruborbactam) in Pyelonephritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Ceftibuten + Xeruborbactam) in Pyelonephritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Ceftibuten + Xeruborbactam) in Pyelonephritis Drug Details: The fixed dose combination...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ALLO-501A in Diffuse Large B-Cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ALLO-501A in Diffuse Large B-Cell Lymphoma Drug Details: ALLO-501A is under development for the treatment...
-
Product Insights
NewPyelonephritis – Drugs In Development, 2024
Empower your strategies with our Pyelonephritis – Drugs In Development, 2024 report and make more profitable business decisions. Pyelonephritis is a specific type of urinary tract infection (UTI) that generally begins in the urethra or bladder and travels up into the kidneys. Signs and symptoms include fever, abdominal pain, frequent urination, nausea and vomiting, confusion, and back or flank pain. Predisposing factors include weakened immune system, obstruction in the urinary tract, and damage to nerves around the bladder. Treatment includes antibiotics....
-
Product Insights
NewAcinetobacter Infections – Drugs In Development, 2024
Empower your strategies with our Acinetobacter Infections – Drugs In Development, 2024 report and make more profitable business decisions. Acinetobacter is a gram-negative coccobacillus. Acinetobacter infections are uncommon but, when they occur, usually involve organ systems that have a high fluid content (respiratory tract, CSF, peritoneal fluid, or urinary tract). Symptoms include fever and red, swollen, warm, or painful skin areas or wounds. Predisposing factors include weak immune system, poor hygiene, and recent surgery or procedure. The Acinetobacter Infections drugs in...
-
Product Insights
NewUrinary Tract Infections – Drugs In Development, 2024
Empower your strategies with our Urinary Tract Infections – Drugs In Development, 2024 report and make more profitable business decisions. A urinary tract infection (UTI) is a bacterial infection that can occur in any part of the urinary system, including the kidneys, bladder, ureters, and urethra. Common symptoms include pain or burning during urination, frequent urination, urgency, lower abdominal discomfort, and cloudy or foul-smelling urine. UTIs are more common in women, and risk factors include factors such as sexual activity, urinary...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AMX-3009 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AMX-3009 in Solid Tumor Drug Details: AMX-3009 is under development for the treatment of HER2...